+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Radiopharmaceutical Theranostics Market Report and Forecast 2023-2031

  • PDF Icon


  • 140 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855138
The global radiopharmaceutical theranostics market size was valued at USD 2.4 billion in 2022, driven by the increasing prevalence of cancer and the need for effective and precise treatment options across the globe. The market size is anticipated to grow at a CAGR of 13.8% during the forecast period of 2023-2031 to achieve a value of USD 7.7 billion by 2031.

Radiopharmaceutical Theranostics: Introduction

Radiopharmaceutical theranostics is an emerging field in nuclear medicine that combines diagnostic imaging and therapeutic applications using radiopharmaceuticals. It involves the use of radiolabeled compounds that can both diagnose and treat specific diseases, such as cancer. The theranostic approach allows for personalized medicine, as it enables targeted therapy based on individual patient characteristics. The concept of theranostics revolves around the idea of using a single compound that has both diagnostic and therapeutic properties. Through the use of specific radionuclides, these compounds can be tracked within the body to diagnose and visualize diseases, while also delivering targeted radiation therapy to the affected tissues. The introduction of radiopharmaceutical theranostics has transformed the way certain diseases, such as cancer, are diagnosed and treated. It offers the potential for more accurate and early detection, improved staging and monitoring of disease progression, and more effective therapy with reduced side effects.

Key Trends in the Global Radiopharmaceutical Theranostics Market

Key trends in the radiopharmaceutical theranostics market include:

  • Increasing prevalence of cancer: The rising incidence of cancer worldwide is driving the demand for effective and targeted treatment options. Radiopharmaceutical theranostics offers the potential for precise tumor targeting and treatment, leading to improved patient outcomes
  • Advancements in imaging and therapeutic agents: The development of novel radiopharmaceuticals and imaging agents with improved specificity and efficacy is a significant trend in the market. This includes the use of alpha and beta emitters, as well as the combination of different radionuclides for targeted therapy
  • Growing importance of personalized medicine: Radiopharmaceutical theranostics aligns with the concept of personalized medicine by tailoring treatment based on individual patient characteristics. This approach enables healthcare professionals to select the most appropriate therapy and monitor treatment response in real time
  • Integration of molecular imaging and nuclear medicine: The integration of molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), with theranostic agents allows for precise localization and characterization of disease. This combination enhances the accuracy of diagnosis and treatment planning
  • Regulatory approvals and market expansion: With the increasing acceptance and success of radiopharmaceutical theranostics, there is a growing focus on obtaining regulatory approvals for new radiopharmaceuticals and expanding market access. This includes efforts to streamline regulatory pathways and ensure the availability of theranostic agents in different regions
  • Collaboration and partnerships: The development and commercialization of radiopharmaceutical theranostics require collaboration among various stakeholders, including pharmaceutical companies, research institutions, and healthcare providers. Partnerships and collaborations facilitate the exchange of knowledge, resources, and expertise to accelerate the development and adoption of theranostic agents

Global Radiopharmaceutical Theranostics Market Segmentations

Market Breakup by Product Type

  • Alpha Emitters
  • Beta Emitters
  • Positron Emission Tomography (PET) Tracers

Market Breakup by Radioisotope

  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • 18F
  • Y-90
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Copper (Cu) 64
  • Others

Market Breakup by Source

  • Nuclear Reactors
  • Cyclotrons

Market Breakup by Applications

  • Targeted Therapeutic
  • Companion Diagnostic
  • Others

Market Breakup by Indications

  • Oncology
  • Cardiology
  • Neurology
  • Others

Market Breakup by End User

  • Hospitals
  • Diagnostic Imaging Centers
  • Academic and Research Institutes
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Radiopharmaceutical Theranostics Market Scenario

The market for radiopharmaceutical theranostics is witnessing significant growth and is poised to expand in the coming years. Radiopharmaceutical theranostics combines diagnostic imaging and therapeutic applications using radiolabeled compounds, providing a personalized and targeted approach to disease management.

The market is primarily driven by the increasing prevalence of cancer and the need for effective and precise treatment options. Radiopharmaceutical theranostics offers the potential for improved tumor targeting and treatment response monitoring, leading to enhanced patient outcomes.

Advancements in imaging and therapeutic agents are playing a crucial role in shaping the market. Researchers and pharmaceutical companies are developing novel radiopharmaceuticals and imaging agents with improved specificity and efficacy. This includes the use of alpha and beta emitters, as well as the combination of different radionuclides for targeted therapy.

The concept of personalized medicine is gaining prominence, and radiopharmaceutical theranostics aligns well with this approach. By tailoring treatment based on individual patient characteristics, healthcare professionals can provide more precise and effective therapy.

Global Radiopharmaceutical Theranostics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Novartis AG
  • Aurobindo Pharma
  • Bayer AG
  • Blue Earth Diagnostics
  • Cardinal Health
  • Clarity Pharmaceuticals
  • GE Healthcare
  • Jubliant Radiopharma
  • Navidea Biopharmaceuticals, Inc
  • Telix Pharmeceuticals
  • Lantheus Medical Imaging
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Radiopharmaceutical Theranostics Market Overview
3.1 Global Radiopharmaceutical Theranostics Market Historical Value (2016-2022)
3.2 Global Radiopharmaceutical Theranostics Market Forecast Value (2023-2031)
4 Global Radiopharmaceutical Theranostics Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Radiopharmaceutical Theranostics Market Segmentation
5.1 Global Radiopharmaceutical Theranostics Market by Product Type
5.1.1 Market Overview
5.1.2 Alpha Emitters
5.1.3 Beta Emitters
5.1.4 Positron Emission Tomography (PET) Tracers
5.2 Global Radiopharmaceutical Theranostics Market by Radioisotope
5.2.1 Market Overview
5.2.2 Technetium-99
5.2.3 Gallium-68
5.2.4 Iodine-131
5.2.5 Iodine-123
5.2.6 18F
5.2.7 Y-90
5.2.8 Lutetium (Lu) 177
5.2.9 Copper (Cu) 67
5.2.10 Copper (Cu) 64
5.2.11 Others
5.3 Global Radiopharmaceutical Theranostics Market by Source
5.3.1 Market Overview
5.3.2 Nuclear Reactors
5.3.3 Cyclotrons
5.4 Global Radiopharmaceutical Theranostics Market by Applications
5.4.1 Market Overview
5.4.2 Targeted Therapeutic
5.4.3 Companion Diagnostic
5.4.4 Others
5.5 Global Radiopharmaceutical Theranostics Market by Indications
5.5.1 Market Overview
5.5.2 Oncology
5.5.3 Cardiology
5.5.4 Neurology
5.5.5 Others
5.6 Global Radiopharmaceutical Theranostics Market by End User
5.6.1 Market Overview
5.6.2 Hospitals
5.6.3 Diagnostic Imaging Centers
5.6.4 Academic and Research Institutes
5.6.5 Others
5.7 Global Radiopharmaceutical Theranostics Market by Region
5.7.1 Market Overview
5.7.2 North America
5.7.3 Europe
5.7.4 Asia Pacific
5.7.5 Latin America
5.7.6 Middle East and Africa
6 North America Radiopharmaceutical Theranostics Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Radiopharmaceutical Theranostics Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Radiopharmaceutical Theranostics Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.6 Australia
8.7 Others
9 Latin America Radiopharmaceutical Theranostics Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Radiopharmaceutical Theranostics Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.5 Others
16 Supplier Landscape
16.1 Novartis AG
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisition
16.1.5 Certifications
16.2 Aurobindo Pharma
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisition
16.2.5 Certifications
16.3 Bayer AG
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisition
16.3.5 Certifications
16.4 Blue Earth Diagnostics
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisition
16.4.5 Certifications
16.5 Cardinal Health
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisition
16.5.5 Certifications
16.6 Clarity Pharmaceuticals
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisition
16.6.5 Certifications
16.7 GE Healthcare
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisition
16.7.5 Certifications
16.8 Jubliant Radiopharma
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisition
16.8.5 Certifications
16.9 Navidea Biopharmaceuticals, Inc.
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisition
16.9.5 Certifications
16.10 SOFIE
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisition
16.10.5 Certifications
16.11 Telix Pharmeceuticals
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisition
16.11.5 Certifications
16.12 Lantheus Medical Imaging
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisition
16.12.5 Certifications
17 Global Radiopharmaceutical Theranostics Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Novartis AG
  • Aurobindo Pharma
  • Bayer AG
  • Blue Earth Diagnostics
  • Cardinal Health
  • Clarity Pharmaceuticals
  • GE Healthcare
  • Jubliant Radiopharma
  • Navidea Biopharmaceuticals, Inc.
  • Telix Pharmeceuticals
  • Lantheus Medical Imaging



Table Information